Earlier this month we discussed the emergence of overlap among psychedelics companies’ drug development pipelines. In the context of such overlap among the most popular indications (most of which are related to mental health ailments) we are now seeing companies announce remarkably distinct ones. This week, for example, PharmaDrug—who earlier this month revealed plans to investigate DMT for stroke…
